乙型肝炎病毒（HBV）感染的全球负担仍然很高，慢性乙型肝炎（CHB）患者患肝硬化和肝细胞癌（HCC）的风险显着增加。抗病毒治疗的最终目标是实现乙肝病毒的绝育治愈。这就需要消除肝内共价闭合环状 DNA (cccDNA) 并彻底根除整合的 HBV DNA。本文旨在总结HBV整合的致癌作用以及清除HBV整合在绝育治疗中的意义。它特别关注 HBV 整合导致 HCC 的分子机制，包括调节原癌基因和肿瘤抑制基因的表达、诱导染色体不稳定以及截短的突变 HBV 蛋白的表达。该综述还强调了抗病毒治疗在减少 HBV 整合和预防 HBV 相关 HCC 方面的影响。此外，该综述还为慢性乙型肝炎治疗的未来目标提供了见解。目前抑制和消除HBV DNA整合的策略主要包括抗病毒治疗、RNA干扰和基因编辑技术。总体而言，HBV 整合值得进一步研究，并有可能作为 CHB 和 HBV 相关 HCC 的生物标志物。© 2024。作者。

The global burden of hepatitis B virus (HBV) infection remains high, with chronic hepatitis B (CHB) patients facing a significantly increased risk of developing cirrhosis and hepatocellular carcinoma (HCC). The ultimate objective of antiviral therapy is to achieve a sterilizing cure for HBV. This necessitates the elimination of intrahepatic covalently closed circular DNA (cccDNA) and the complete eradication of integrated HBV DNA. This review aims to summarize the oncogenetic role of HBV integration and the significance of clearing HBV integration in sterilizing cure. It specifically focuses on the molecular mechanisms through which HBV integration leads to HCC, including modulation of the expression of proto-oncogenes and tumor suppressor genes, induction of chromosomal instability, and expression of truncated mutant HBV proteins. The review also highlights the impact of antiviral therapy in reducing HBV integration and preventing HBV-related HCC. Additionally, the review offers insights into future objectives for the treatment of CHB. Current strategies for HBV DNA integration inhibition and elimination include mainly antiviral therapies, RNA interference and gene editing technologies. Overall, HBV integration deserves further investigation and can potentially serve as a biomarker for CHB and HBV-related HCC.© 2024. The Author(s).